Cargando…
Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis
Multiple sclerosis (MS) is a serious autoimmune demyelinating disease leading to loss of neurological function. The design and synthesis of various altered peptide ligands of immunodominant epitopes of myelin proteins to alter the autoimmune response, is a promising therapeutic approach for MS. In t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450228/ https://www.ncbi.nlm.nih.gov/pubmed/26082772 http://dx.doi.org/10.3389/fimmu.2015.00136 |
_version_ | 1782373974802432000 |
---|---|
author | Day, Stephanie Tselios, Theodore Androutsou, Maria-Eleni Tapeinou, Anthi Frilligou, Irene Stojanovska, Lily Matsoukas, John Apostolopoulos, Vasso |
author_facet | Day, Stephanie Tselios, Theodore Androutsou, Maria-Eleni Tapeinou, Anthi Frilligou, Irene Stojanovska, Lily Matsoukas, John Apostolopoulos, Vasso |
author_sort | Day, Stephanie |
collection | PubMed |
description | Multiple sclerosis (MS) is a serious autoimmune demyelinating disease leading to loss of neurological function. The design and synthesis of various altered peptide ligands of immunodominant epitopes of myelin proteins to alter the autoimmune response, is a promising therapeutic approach for MS. In this study, linear and cyclic peptide analogs based on the myelin basic protein 83–99 (MBP(83–99)) immunodominant epitope conjugated to reduced mannan via the (KG)(5) and keyhole limpet hemocyanin (KLH) bridge, respectively, were evaluated for their biological/immunological profiles in SJL/J mice. Of all the peptide analogs tested, linear MBP(83–99)(F(91)) and linear MBP(83–99)(Y(91)) conjugated to reduced mannan via a (KG)(5) linker and cyclic MBP(83–99)(F(91)) conjugated to reduce mannan via KLH linker, yielded the best immunological profile and constitute novel candidates for further immunotherapeutic studies against MS in animal models and in human clinical trials. |
format | Online Article Text |
id | pubmed-4450228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-44502282015-06-16 Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis Day, Stephanie Tselios, Theodore Androutsou, Maria-Eleni Tapeinou, Anthi Frilligou, Irene Stojanovska, Lily Matsoukas, John Apostolopoulos, Vasso Front Immunol Immunology Multiple sclerosis (MS) is a serious autoimmune demyelinating disease leading to loss of neurological function. The design and synthesis of various altered peptide ligands of immunodominant epitopes of myelin proteins to alter the autoimmune response, is a promising therapeutic approach for MS. In this study, linear and cyclic peptide analogs based on the myelin basic protein 83–99 (MBP(83–99)) immunodominant epitope conjugated to reduced mannan via the (KG)(5) and keyhole limpet hemocyanin (KLH) bridge, respectively, were evaluated for their biological/immunological profiles in SJL/J mice. Of all the peptide analogs tested, linear MBP(83–99)(F(91)) and linear MBP(83–99)(Y(91)) conjugated to reduced mannan via a (KG)(5) linker and cyclic MBP(83–99)(F(91)) conjugated to reduce mannan via KLH linker, yielded the best immunological profile and constitute novel candidates for further immunotherapeutic studies against MS in animal models and in human clinical trials. Frontiers Media S.A. 2015-04-07 /pmc/articles/PMC4450228/ /pubmed/26082772 http://dx.doi.org/10.3389/fimmu.2015.00136 Text en Copyright © 2015 Day, Tselios, Androutsou, Tapeinou, Frilligou, Stojanovska, Matsoukas and Apostolopoulos. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Day, Stephanie Tselios, Theodore Androutsou, Maria-Eleni Tapeinou, Anthi Frilligou, Irene Stojanovska, Lily Matsoukas, John Apostolopoulos, Vasso Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis |
title | Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis |
title_full | Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis |
title_fullStr | Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis |
title_full_unstemmed | Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis |
title_short | Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis |
title_sort | mannosylated linear and cyclic single amino acid mutant peptides using a small 10 amino acid linker constitute promising candidates against multiple sclerosis |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450228/ https://www.ncbi.nlm.nih.gov/pubmed/26082772 http://dx.doi.org/10.3389/fimmu.2015.00136 |
work_keys_str_mv | AT daystephanie mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis AT tseliostheodore mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis AT androutsoumariaeleni mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis AT tapeinouanthi mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis AT frilligouirene mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis AT stojanovskalily mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis AT matsoukasjohn mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis AT apostolopoulosvasso mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis |